EP Wealth Advisors LLC Purchases 6,872 Shares of Haleon plc (NYSE:HLN)

EP Wealth Advisors LLC boosted its position in Haleon plc (NYSE:HLN) by 34.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 26,982 shares of the company’s stock after acquiring an additional 6,872 shares during the period. EP Wealth Advisors LLC’s holdings in Haleon were worth $285,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Fortitude Family Office LLC purchased a new position in shares of Haleon in the third quarter worth about $28,000. Cultivar Capital Inc. bought a new position in Haleon in the 2nd quarter worth approximately $40,000. Prospera Private Wealth LLC purchased a new position in Haleon in the 3rd quarter valued at approximately $57,000. BOKF NA raised its holdings in Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after acquiring an additional 2,842 shares during the period. Finally, Rothschild Investment LLC purchased a new stake in shares of Haleon during the second quarter worth $60,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Up 0.3 %

Shares of NYSE:HLN opened at $9.76 on Friday. The firm has a fifty day moving average price of $9.75 and a two-hundred day moving average price of $9.51. The company has a market cap of $44.18 billion, a price-to-earnings ratio of 28.71, a PEG ratio of 2.95 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a one year low of $7.89 and a one year high of $10.80.

Wall Street Analyst Weigh In

HLN has been the subject of several recent research reports. Morgan Stanley lifted their price target on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. UBS Group raised Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Haleon currently has an average rating of “Buy” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.